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Abstract 
Background: Obesity is associated with multiple adverse cardiovascular conditions and may increase the risk of ven-
tricular tachyarrhythmias (VT/VF). There is limited data on the association between obesity and risk of VT/VF requiring 
appropriate implantable cardioverter-defibrillator (ICD) therapies and the effectiveness of cardiac resynchronization 
therapy (CRT) to reduce risk for VT/VF. The multicenter automatic defibrillator implantation trial with cardiac resyn-
chronization therapy (MADIT-CRT) was design to investigate effectiveness of CRT therapy to reduce cardiovascular 
outcome for patients with heart failure (HF) and reduced ejection fraction.
Methods and results: We identified patients enrolled in the MADIT CRT trial as obese (n = 433) and non-obese 
(n = 845) and analyzed their risk for appropriate device therapy for VT/VF, repeated VT/VF events, fast VT/VF, as well 
as events after first VT/VF episodes. Obesity was defined as body mass index (BMI) ≥30 kg/m2. Among ICD patients, 
the risk of first appropriate ICD therapy for VT/VF at 3 years was similar between obese and non-obese patients (23 vs. 
21 %, p = 0.76). CRT-D treatment reduced the risk of first appropriate ICD therapy both in non-obese ([HR]; 0.58 [CI]: 
0.42–0.79; p < 0.001) and obese patients (HR 0.75, 95 % CI 0.5–1.38; p = 0.179) (interaction p value 0.323). Similarly, a 
significant reduction in the risk of fast VT/VF was observed in non-obese patients ([HR]; 0.49 [CI]: 0.33–0.73; p < 0.001) 
and obese ([HR]; 0.49 [CI]: 0.29–0.81; p < 0.01), (interaction p value 0.984).
Conclusion: Obese and non-obese patients with mild heart failure have a similar risk of ventricular tachyarrhythmias. 
Obesity in mild heart failure did not diminish the clinical benefit of cardiac resynchronization therapy to reduce risk for 
appropriate ICD therapy.
Clinical trial registration http://clinicaltrials.gov/ct2/show/NCT00180271
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Background
Obesity contributes to the development of several risk 
factors that are associated with cardiac arrhythmias, 
including metabolic syndrome, ischemic heart disease [1, 
2], atrial enlargement, left ventricular hypertrophy [3], 
systolic and diastolic heart failure [4, 5] and sleep apnea 
[6]. The cardiac structural abnormalities that are asso-
ciated with obesity may potentially increase the risk for 
ventricular arrhythmogenesis including myocyte hyper-
trophy, fibrosis, focal myocardial disarray, fatty infiltra-
tion and increased epicardial fat [7]. Patients with obesity 
have also been shown to have disrupted pattern of gap 
junction protein expression and distribution. [8] Obesity 
Open Access
Cardiovascular Diabetology
*Correspondence:  barbara_szepietowska@URMC.Rochester.edu 
Heart Research Follow-up Program, Cardiology Division, University 
of Rochester Medical Center, 265 Crittenden Blvd., PO Box 653, Rochester, 
NY 14642, USA
Page 2 of 8Szepietowska et al. Cardiovasc Diabetol  (2016) 15:93 
is also associated with delayed ventricular repolarization 
as evidenced by prolongation of QT/QTc interval [8, 9]. 
Additional mechanism responsible for increased risk 
for arrhythmias is sympathetic over activation present 
in patients with obesity [10]. These changes in part may 
contribute to the increased propensity to VT/VF in obese 
individuals [11].
The association between atrial fibrillation and obesity 
has been thoroughly investigated [12–16], however the 
association between ventricular arrhythmias and obesity 
is not fully understood. Increased prevalence for cardiac 
tachyarrhythmias and increased risk of sudden cardiac 
death was reported in obese post myocardial infarction 
patients with abnormal ejection fraction [17–19].
In our previous MADIT II, where ICD therapy was 
tested for prevention for sudden cardiac death, we 
observed that obesity is an independent risk factor for 
VT/VF [17]. The aim of the current study was to: (i) 
evaluate the association between obesity and the risk of 
appropriate implantable cardioverter-defibrillator (ICD) 
therapy delivered for VT/VF in patients with mild heart 
failure and reduced ejection fraction; (ii) evaluate the 
effectiveness of cardiac resynchronization therapies to 
reduce risk for VT/VF in obese and non-obese patients, 
(iii) to assess the prognostic implications of first VT/VF 
on the subsequent tachyarrhythmia event and all-cause 
mortality in this population.
Methods
Study population
The results and the protocol of the Multicenter Auto-
matic Defibrillator Implantation Trial with Cardiac 
Resynchronization Therapy (MADIT-CRT) trial have 
been previously reported [20]. From December 22nd, 
2004, through June 24th, 2009 a total of 1820 patients 
were enrolled at 110 centers in US, Canada and in 
Europe. Patients of either sex who were at least 21 years 
old, with ischemic cardiomyopathy (NYHA class I or II) 
or non-ischemic cardiomyopathy (NYHA class II only), 
sinus rhythm, a left ventricular ejection fraction (LVEF) 
of 30 % or less and prolonged intraventricular conduction 
(QRS duration ≥130 ms) were randomly assigned in 3:2 
ratio to CRT-D or ICD only. Patients had an ambulatory 
follow-up one-month after the device implantation, and 
every 3  months thereafter until the termination of the 
trial. The mean follow-up of the enrolled patients was 
40  months. All patients had clinical evaluation at each 
follow up visit or at any meaningful clinical event.
Following the primary publication of MADIT-CRT, 
subsequent analyses showed that the benefit of CRT-D in 
the trial was restricted to patients with left bundle branch 
block (LBBB) [21]. Patients with obesity were defined as 
BMI ≥30 kg/m2 at the baseline visit [22].
Device programming and Interrogation
Commercially available transvenous devices from Bos-
ton Scientific and standard techniques were used in the 
MADIT-CRT. Devices were programmed according to 
the study protocol [23] to monitor therapy, with a pro-
tocol recommendation to a setting of the VT zone at 180 
beats/min (bpm) and the VF zone at 210 bpm. Sensitiv-
ity was programmed according to physician discretion. 
Detection times were 2.5  s for the VT zone and 1.0  s 
for the VF zone. The protocol recommended program-
ming the VT zone with first therapy to burst-type anti-
tachycardia pacing with 8 pulses at 88 % of the measured 
cycle length with a 10-milliseconds decrement between 
bursts, then shock therapy; second therapy was recom-
mended to be shock at the defibrillation threshold plus 
at least 10 J (if possible). The remaining therapies were to 
be maximal energy shocks. All shocks were biphasic. The 
ICDs were interrogated quarterly, after which ICD data 
and disks were sent to the core laboratory for categori-
zation and final adjudication of detected arrhythmias. 
Arrhythmia episode was defined as any type of therapy 
rendered including antitachycardia pacing and shock. 
The adjudication committee adjudicated the episode. VT 
was defined as the ventricular rate up to 250  bpm; VF 
was defined as ventricular rate faster than 250 bpm with 
disorganized ventricular electrographs. Only appropri-
ate ICD therapy delivered for VT (≥180 bpm) or VF was 
considered in the present study.
End points definition
The end point of the current study was first VT/VF 
requiring appropriate ICD therapy, repeated VT/VF 
requiring appropriate ICD therapy, VT/VF or death 
whichever came first, fast VT/VF defined as  >200  bpm 
and VT/VF requiring ICD shocks.
Statistical analysis
Baseline clinical characteristics were compared using 
the nonparametric Kruskal–Wallis test for continuous 
variables and the Chi square-test or Fisher’s exact test 
for dichotomous variables, as appropriate. We performed 
Kaplan–Meier survival analyses of unadjusted cumula-
tive event rates stratified by obesity with the log-rank test 
for determination of statistical significance.
The Cox proportional hazards multivariate regres-
sion model was used to estimate hazard ratios for risk 
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of appropriate ICD therapy delivered for (VT/VF), VT/
VF/death, VT/VF greater than 200 bpm and shock deliv-
ered for VT/VF. These hazard ratios were estimated for 
two separate groups: non-obese and obese patients. The 
independent variables were chosen using the best sub-
sets selection method and adjustment included: assigned 
treatment, race (Black/African American), age at enroll-
ment, creatinine ≥1.4, female, left ventricle end diastolic 
volume index, myocardial infarction prior to enroll-
ment, enrollment NYHA classification, prior hospitali-
zation during preceding year, QRS <150 ms, ventricular 
arrhythmias requiring treatment prior to enrolment. The 
full multivariable model is presented in Additional 
file  1: Table  S1. We followed this statistical methodol-
ogy because we wanted to develop a parsimonious model 
which excluded variables which were not significantly 
predictive of the endpoints and would have very little 
impact on the results. In this way we attempted to maxi-
mize statistical power, an important consideration in 
subgroup analysis. To assess the CRT-D treatment differ-
ences between patients by obesity, a treatment-by-obe-
sity medication interaction term was included in the Cox 
proportional hazard regression models. A two degree 
of freedom Wald test was done to assess the strength of 
the interaction between the groups and CRT-D treat-
ment. All statistical tests were two-sided and a p < 0.05 
was considered statistically significant, because of the 
numerous statistical tests, the p value reported should 
be considered as nominal and not corrected for multiple 
comparison. Analyses were carried out with SAS soft-
ware (version 9.3, SAS institute, Cary, North Carolina).
Results
MADIT CRT in total included 1820, 539 were excluded 
due to non-LBBB and 17 due to not having BMI at base-
line. The study population consisted of 1264 patients with 
LBBB including 833 (66  %) non-obese and 431 (34  %) 
obese patients. Clinical and demographic characteris-
tics of the study population are presented in Table 1. In 
summary, obese patients were younger by about 5 years, 
more often presented with diabetes and hypertension, 
and had longer QRS duration, higher resting heart rate, 
systolic and diastolic blood pressure, higher glomerular 
filtration rate (GFR) and lower plasma brain natriuretic 
peptide (BNP) () levels. Patients with obesity more often 
reported usage of diuretics including aldosterone recep-
tor antagonists. ICD programming was also not differ-
ent between non-obese and obese. A total of 266 (21 %) 
LBBB patients experienced at least one tachyarrhythmia 
event at a heart rate ≥180 beats/min.
Table 1 Clinical characteristics of LBBB patients by obesity 
in MADIT-CRT
Non-obese n = 833 Obese n = 431 p value
Demographics
 Age, mean ± SD, y 65.8 ± 10.6 61.1 ± 10.6 <0.001
 Women, n (%) 263 (32) 125 (29) 0.348
 White n (%) 764 (92) 389 (90) 0.272
Cardiac history n (%)
 CRT-D assigned 
n (%)
498 (60) 259 (60) 0.915
 Ischemic cardiomyo-
pathy
374 (45) 183 (42) 0.408
 Diabetes 216 (26) 166 (39) <0.001
 Hypertension 497 (60) 300 (70) <0.001
 Prior MI 268 (33) 135 (32) 0.761
 Prior CABG 191 (23) 90 (21) 0.401
 Prior HF hospitaliza-
tion
310 (38) 172 (40) 0.421
 Past atrial arrhyth-
mias
93 (11) 47 (11) 0.892
 Past ventricular 
arrhythmias
47 (6) 34 (8) 0.121
Clinical characteristics at enrolment mean ± SD
 LVEF (%) 28.9 ± 3.5 28.5 ± 3.4 0.132
 QRS duration (ms) 162.1 ± 19.3 164.7 ± 19.0 0.012
 Resting heart rate 
(bpm)
67.7 ± 10.9 69.2 ± 10.9 0.019
 Systolic blood pres-
sure (mmHg)
122.2 ± 17.2 123.6 ± 17.0 0.090
 Diastolic blood pres-
sure (mmHg)
70.7 ± 9.9 72.9 ± 10.7 0.002
 Brain natriuretic 
peptide pg/dl
134.8 ± 168.9 78.7 ± 91.9 <0.001
 Glomerular filtration 
rate ml/m2
68.5 ± 19.8 70.8 ± 20.4 0.046
Medications, n (%)
 ACE inhibitor or 
aldosterone recep-
tor antagonists
797 (96) 418 (97) 0.254
 Aldosterone recep-
tor antagonists
254 (30) 172 (40) <0.001
 Aspirin 500 (60) 275 (64) 0.191
 Beta-blockers 779 (94) 408 (95) 0.419
 Diuretic 536 (64) 328 (76) <0.001
 Statins 522 (63) 281 (65) 0.375
ICD programming
 Rate of lowest 
VT <180 bpm
153 (20) 63 (16) 0.060
 Rate of highest 
VF >210 bpm
79 (10) 45 (10) 0.650
 ATP (%) 743 (91) 399 (93) 0.267
 Cut-off rate of lowest 
VT zone (ms)
177 ± 7 178 ± 7 0.029
 Cut-off rate of VF 
zone (ms)
209 ± 9 210 ± 8 0.357
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The appropriate ICD therapies in obese and non-obese 
patients
Among patients in the ICD arm only, the risk for appro-
priate ICD therapy at 3 years was similar between obese 
and non-obese patients for VT/VF, VF/VF/death, as well 
as shock delivered for VT/VF, and VT/VF higher than 
200 (Fig.  1). Multivariable analysis consistently showed 
that risk for appropriate therapy in ICD arm was similar 
for non-obese and obese patients (Table 2).
In our population non-obese and obese presented with 
similar rate for appropriate therapy in ICD arm, CRT-D 
arm and both arm combined (Table  3) and (Additional 
file 2: Figure S1).
The effect of CRT-D on the risk of appropriate implantable 
cardioverter-defibrillator therapy
Kaplan–Meier survival analysis showed the cumula-
tive probability of the of first appropriate ICD therapies 
delivered for VT/VF was significantly decreased for non-
obese patients obese did not demonstrate a decreased 
when CRT-D was compared to ICD group only (Fig. 2).
However, multivariable analysis showed that CRT-D 
treatment significantly reduced the risk of appropriate 
ICD therapy in non-obese patients ([HR]; 0.58 [CI]: 0.42–
0.79; p < 0.001) and to a lesser degree in obese patients 
(HR 0.75, 95  % CI 0.5–1.38; p =  0.179), however inter-
action p value was not significant p  =  0.323. Signifi-
cant reduction in risk of fast VT/VF was observed in 
Fig. 1 Percentage of patients with appropriate ICD therapy for VT/VF at 3 years in non-obese and obese in ICD arm
Table 2 Risk of  appropriate implantable cardioverter-
defibrillator therapy in  obese versus  non-obese patients 
in ICD arm
After adjustment for: race (Black/African American), age at enrollment, 
creatinine ≥1.4, female sex, left ventricle end diastolic volume index, 
myocardial infarction prior to enrollment, enrollment NYHA classification, prior 
hospitalization during prior year, QRS <150, ventricular arrhythmias requiring 
treatment prior to enrolment













Shock delivered for VT/VF 76 0.96
(0.67–1.79)
0.745
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non-obese ([HR]; 0.49 [CI]: 0.33–0.73; p  <  0.001) and 
obese patients ([HR]; 0.49 [CI]: 0.29–0.81; p  <  0.01) 
(Fig. 3).
The effect of CRT-D on the risk of recurrent appropriate 
implantable cardioverter—defibrillator therapy and death
Among patients who experienced a first incidence of VT/
VF, Kaplan–Meier survival analysis showed no statisti-
cally significant difference between treatment groups by 
obesity status with regards to the occurrence of a sec-
ond VT/VF (Fig.  4). Consistently, multivariable model 
showed that the benefit of CRT to reduce the VT/VF end 
point was not evident in non-obese and obese patients 
among those who experienced a first event (Table  4). 
CRT-D therapy was effective in reducing VT/VF faster 
than 200 bpm (p = 0.086) and VT/VF episodes requiring 
ICD shocks (p = 0.031) in obese patients only.
Among non-obese patients who had an appropri-
ate ICD therapy a higher risk of death was observed 
([HR]; 2.02 [CI]: 1.14–3.57; p = 0.014), similarly to obese 
patients ([HR]; 2.79 [CI]: 1.37–5.68; p =  004) (Table  4) 
comparing to those who did not have appropriate ICD 
therapy.
Discussion
To our knowledge, the present study is the first to 
assess the effect of obesity on the risk of VT/VF and 
recurrent VT/VF in response to CRT-D treatment. In 
our current analysis obesity was not associated with 
a higher risk of first and subsequent ventricular tach-
yarrhythmias and did not diminish clinical benefit of 
cardiac resynchronization therapy to reduce risk for 
appropriate therapy delivered for VT/VF. Consistently 
both non-obese and obese patients showed higher risk 
for death after the occurrence of the appropriate ICD 
therapy.
Our previous MADIT II study reported a higher rate 
of VT/VF in obese post-infarction patients [17]. MADIT 
II was a post-infarction population study without a 
requirement of heart failure. The overall rate for VT/VF 
was 10 % higher than in MADIT-CRT. The MADIT CRT 
population consisted of patients with both ischemic and 
non-ischemic cardiomyopathy [24]. Additionally, phar-
macological treatment and prevention strategies for heart 
failure optimize over the years and this may contribute to 
lower rate for VT/VF in current population [25]. Success 
strategies for ICD implantation are also similar in obese 
and non-obese [26]. CRT-D reduces the risk for heart 
failure, death and VT/VF [20, 27, 28], but significant evi-
dence suggests that the benefit derived from CRT varies 
Table 3 Rates of  recurrent appropriate ICD therapies 
for VT/VF per 100 patient-years at risk assessed at a 3-year 
follow-up
Treatment arm Events Non-obese Obese p value
ICD VT/VF 56.82 44.58 0.244
VT/VF/Death 61.3 48.44 0.237
VT/VF greater than 
200 bpm
23.94 19.29 0.384
Shock delivered for 
VT/VF
22.71 18.43 0.522
CRT-D VT/VF 27.97 40.22 0.453
VT/VF/death 30.95 42.85 0.359
VT/VF greater than 
200 bpm
9.25 7.49 0.495
Shock delivered for 
VT/VF
8.72 5.41 0.171
Fig. 2 Cumulative probability of VT/VF by treatment arm in: a non-
obese and b obese patients
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by baseline conduction disturbances therefore our study 
included only patients with LBBB [21].
The mechanism of cardiac arrhythmias in obesity 
includes: heart remodeling including left ventricle hyper-
trophy, subclinical systolic impairment and diastolic dys-
function, pericardial adipose tissue inflammatory cytokine 
secretion and sympathetic over-activity [11]. Pathologi-
cal myocardial changes such as myocyte hypertrophy, 
fibrosis, focal myocardial disarray, fatty infiltration and 
increased epicardial fat may contribute to increased risk 
of arrhythmias [7]. Despite the strong evidence that obe-
sity may predispose to ventricular arrhythmias our cur-
rent study did not support prior observations. In patients 
with obesity and heart failure, association between body 
mass index and subsequent cardiovascular risk is complex 
and known as “obesity paradox” [29, 30], suggesting that 
role of obesity accompanied establish HF, the effect on 
clinical outcome including risk for VT/VF may be neutral 
or even positive at this stage of disease [31].
In summary, strategies to reduce risk for negative 
health outcomes in people with obesity should be imple-
mented early before the development of HF. This is sup-
ported in our analysis because obese patients are 5 years 
younger than people without obesity. The preventive 
strategies may include adequate body weight monitoring 
which may translate into prevention of HF development 
and consecutive ICD or CRT therapy [19].
Fig. 3 The Effect of CRT-D vs. ICD in obese and non-obese patients on the risk of appropriate implantable cardioverter—defibrillator therapy. (VT/
VF-ventricular tachycardia/ventricular fibrillation)
Page 7 of 8Szepietowska et al. Cardiovasc Diabetol  (2016) 15:93 
Limitation of our study relates to a retrospective and 
nonrandomized nature of this post hoc analysis. An 
adjusted multivariate analysis was performed, taking into 
account many confounders associated with analyzed end 
point and those that played a significant role on this out-
come in our population.
In conclusion, our findings indicate that obesity in mild 
heart failure did not diminish clinical benefit of cardiac 
resynchronization therapy. Patients with obesity should 
be offered CRT-D treatment and obesity should not 
preclude the use of CRT-D treatment when clinically 
indicated.
Additional files
Additional file 1: Table S1. The risk of appropriate implantable cardio-
verter—defibrillator therapy delivered for VTVF a full multivariable model.
Additional file 2: Figure S1. Association between appropriate ICD 
therapy delivered for VT/VF and the BMI level.
Fig. 4 Cumulative probability of VT/VF following a first VT/VF event 
by treatment arm in: a non-obese and b obese patients
Table 4 The effect of  CRT-D in  obese and  non-obese 
patients on  the risk of  subsequent appropriate ICD ther-
apy or death
After adjustment for race (Black/African American), age at enrollment, 
creatinine ≥1.4, female sex, left ventricle end diastolic volume index, 
myocardial infarction prior to enrollment, enrollment NYHA classification, prior 
hospitalization during prior year, QRS <150, ventricular arrhythmias requiring 
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